Literature DB >> 19780673

The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells.

Daniela Schulte1, Martin Vogel, Bettina Langhans, Benjamin Krämer, Christian Körner, Hans Dieter Nischalke, Verena Steinberg, Monika Michalk, Thomas Berg, Jürgen K Rockstroh, Tilman Sauerbruch, Ulrich Spengler, Jacob Nattermann.   

Abstract

Recently, we showed chronic hepatitis C to be associated with increased expression of HLA-E and identified peptide hepatitis C virus (HCV) core amino acids 35-44 as a ligand for HLA-E that stabilizes HLA-E expression, favoring inhibition of natural killer cell cytotoxicity. Here we describe HLA-E-restricted recognition of peptide HCV core amino acids 35-44 by CD8(+) T cells. Frequency of HLA-E-restricted responses was significantly higher in patients homozygous for the HLA-E(R) allele (60% vs 38%; P = .038). Moreover, we found that the HLA-E(R) allelic variant confers protection against chronic infection with HCV genotypes 2 and 3. Taken together, our data indicate an important immunomodulating function of HLA-E in hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19780673     DOI: 10.1086/605889

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  NKG2C deletion is a risk factor of HIV infection.

Authors:  Rachel Thomas; Hui Zhi Low; Katja Kniesch; Roland Jacobs; Reinhold E Schmidt; Torsten Witte
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-03       Impact factor: 2.205

2.  Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.

Authors:  Sung-Jae Park; Young S Hahn
Journal:  Rev Infect       Date:  2010-07-01

3.  Non-classical MHC-Ι genes in chronic hepatitis B and hepatocellular carcinoma.

Authors:  Jian Zhang; Lelin Pan; Luyan Chen; Xiaowen Feng; Lin Zhou; Shusen Zheng
Journal:  Immunogenetics       Date:  2011-10-21       Impact factor: 2.846

4.  Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.

Authors:  Abolghasem Asadi-Saghandi; Ali Shams; Gilda Eslami; Seyed Ali Mirghanizadeh; Ebrahim Eskandari-Nasab
Journal:  Virusdisease       Date:  2016-09-28

Review 5.  NK cells, innate immunity and hepatitis C infection after liver transplantation.

Authors:  Anoma Nellore; Jay A Fishman
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

6.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 7.  The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors.

Authors:  Gabriella Pietra; Chiara Romagnani; Claudia Manzini; Lorenzo Moretta; Maria Cristina Mingari
Journal:  J Biomed Biotechnol       Date:  2010-06-22

Review 8.  The role of MHC class Ib-restricted T cells during infection.

Authors:  Courtney K Anderson; Laurent Brossay
Journal:  Immunogenetics       Date:  2016-07-01       Impact factor: 2.846

Review 9.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

10.  HIV-host interactome revealed directly from infected cells.

Authors:  Yang Luo; Erica Y Jacobs; Todd M Greco; Kevin D Mohammed; Tommy Tong; Sarah Keegan; James M Binley; Ileana M Cristea; David Fenyö; Michael P Rout; Brian T Chait; Mark A Muesing
Journal:  Nat Microbiol       Date:  2016-05-23       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.